Harald Petry
Keine laufenden Positionen mehr
Profil
Harald Petry worked as Director of Research & Development at Amsterdam Molecular Therapeutics (AMT) Holding NV from 2007 to 2013.
He also worked as Principal at Jenapharm GmbH & Co. KG and Berlex Biosciences.
From 2012 to 2017, he served as Chief Scientific Officer at uniQure NV.
Petry holds a doctorate degree from the University of Giessen.
Ehemalige bekannte Positionen von Harald Petry
| Unternehmen | Position | Ende |
|---|---|---|
| UNIQURE N.V. | Technik-/Wissenschafts-/F&E-Leiter | 07.08.2017 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Technik-/Wissenschafts-/F&E-Leiter | 11.03.2013 |
| Berlex Biosciences | Corporate Officer/Principal | - |
Jenapharm GmbH & Co. KG
 Jenapharm GmbH & Co. KG Pharmaceuticals: MajorHealth Technology Jenapharm GmbH & Co. KG manufactures and distributes pharmaceutical products. It offers cures for erectile dysfunction, testosterone deficit, and hyperactivity. It also provides contraceptives, menopause pills, and food supplements. The company was founded in 1950 and is headquartered in Jena, Germany. | Corporate Officer/Principal | - |
Ausbildung von Harald Petry
| University of Giessen | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| UNIQURE N.V. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Jenapharm GmbH & Co. KG
Jenapharm GmbH & Co. KG Pharmaceuticals: MajorHealth Technology Jenapharm GmbH & Co. KG manufactures and distributes pharmaceutical products. It offers cures for erectile dysfunction, testosterone deficit, and hyperactivity. It also provides contraceptives, menopause pills, and food supplements. The company was founded in 1950 and is headquartered in Jena, Germany. | Health Technology |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
| Berlex Biosciences |
